Characterizing the feasibility and performance of real-world tumor progression end points and their association with overall survival in a large advanced non–small-cell lung cancer data set
Our summary
Flatiron’s follow-up study expands the previous pilot to evaluate real-world progression (rwP) abstraction at scale. This study confirmed relatively high completeness and agreement for the approach used in curating rwP events for an EHR dataset of over 30,000 patients with advanced non-small cell lung cancer.
Why this matters
Novel analytical approaches unlock new research avenues but need to be vetted in order to assess their validity. This study shows that Flatiron’s new approach to extract disease progression information from EHR-derived datasets is feasible, scalable and reliable, enabling analyses of associated endpoints (progression-free survival, time to progression) that yield clinically meaningful results.